YM-155 Hydrochloride: Potent Survivin Inhibitor for Cancer Research

Executive Summary: YM-155 hydrochloride is a selective small-molecule inhibitor targeting survivin, an IAP family protein implicated in cancer cell survival (Schwartz 2022). It exhibits nanomolar IC₅₀ (0.54 nM) in vitro, suppresses proliferation across diverse human cancer cell lines, and triggers tumor regression in xenograft models (APExBIO). YM-155 hydrochloride demonstrates minimal off-target effects on other IAPs or BCL-2 family proteins. It has been validated for robust, reproducible results in apoptosis and cytotoxicity assays. Optimal storage and solubility parameters ensure experimental consistency for research workflows.

Biological Rationale

Survivin (BIRC5) is a member of the inhibitor of apoptosis protein (IAP) gene family. It is frequently overexpressed in human cancers and correlates with resistance to apoptosis and treatment failure (Schwartz 2022). Small-molecule inhibitors like YM-155 hydrochloride specifically disrupt the survivin signaling pathway, reducing cancer cell viability and sensitizing cells to chemotherapeutic agents. The selectivity of YM-155 makes it a preferred tool for dissecting apoptosis regulation in cancer biology. By targeting survivin, YM-155 interrupts both anti-apoptotic signaling and mitotic progression in tumor cells. This rationale is foundational for its adoption in mechanistic studies and translational oncology workflows.

Mechanism of Action of YM-155 hydrochloride

YM-155 hydrochloride binds and inhibits survivin, the smallest IAP family member, with high specificity. The compound does not significantly inhibit other IAPs or BCL-2-related proteins at pharmacologically relevant concentrations. Inhibition of survivin disrupts its role in blocking caspase activation, promoting programmed cell death (apoptosis) in cancer cells. YM-155 also impairs survivin’s function in cell division by affecting chromosomal passenger complex integrity. This dual action leads to anti-proliferative and pro-apoptotic effects, as confirmed in cellular and animal models. The compound’s selectivity profile minimizes off-target cytotoxicity, supporting its use in precise apoptosis inhibitor research (APExBIO).

Evidence & Benchmarks

• YM-155 hydrochloride exhibits an IC₅₀ of 0.54 nM against survivin in vitro, confirming high potency (APExBIO, product page).
• The compound induces significant apoptosis and suppresses proliferation in a wide range of human cancer cell lines under in vitro conditions (Schwartz 2022, DOI).
• In xenograft models, YM-155 triggers tumor regression in non-small cell lung cancer (NSCLC), melanoma, bladder, non-Hodgkin lymphoma, and breast cancer models (APExBIO, product page).
• It significantly prolongs survival in animal models bearing metastatic tumors derived from triple-negative breast cancer cell lines (Schwartz 2022, DOI).
• Minimal activity is observed on other IAP family proteins or BCL-2-related proteins at doses selective for survivin inhibition (APExBIO, product page).

This article extends prior scenario-based guidance found in Optimizing Apoptosis Assays by offering detailed benchmarks and rigorous, verifiable performance data for YM-155 hydrochloride, and clarifies selectivity and application limits beyond summary overviews such as Potent Survivin Inhibitor for Cancer Research.

Applications, Limits & Misconceptions

YM-155 hydrochloride is suitable for:

• Apoptosis and cytotoxicity assays in cell-based research.
• Preclinical evaluation of survivin-targeted therapies in xenograft models.
• Mechanistic studies dissecting the IAP pathway and survivin signaling in tumor biology.
• Comparative pharmacology and selectivity profiling relative to other apoptosis inhibitors.

However, YM-155 hydrochloride is not intended for diagnostic or therapeutic (clinical) use. Its efficacy and selectivity depend on appropriate dosing, solvent, and storage protocols. Experimental context (cell line, model organism, and assay readout) may influence observed anti-proliferative effects (Schwartz 2022).

Common Pitfalls or Misconceptions

• YM-155 hydrochloride does not inhibit all IAP family proteins equally; it is highly selective for survivin, with minimal activity on XIAP or cIAPs at standard concentrations.
• It is not a direct BCL-2 family protein inhibitor; experimental designs targeting BCL-2 pathways require alternative compounds.
• Solubility varies by solvent and requires gentle warming or ultrasonic treatment for ethanol or water; improper dissolution may lead to inconsistent dosing.
• Long-term storage of solutions is discouraged; stability is optimal at -20°C and for short-term use only.
• YM-155 is not validated for use in clinical diagnostics or as a drug in patients; it is strictly for scientific research applications.

Workflow Integration & Parameters

YM-155 hydrochloride (A3947) from APExBIO is available as a solid (molecular weight: 398.84; formula: C₂₀H₁₉ClN₄O₃). For experimental use, dissolve at ≥19.45 mg/mL in DMSO, ≥4.34 mg/mL in ethanol (with gentle warming and ultrasound), or ≥48.1 mg/mL in water (with ultrasound). Store at -20°C; use solutions promptly to maintain potency (YM-155 hydrochloride product page). For apoptosis or proliferation assays, titrate concentrations based on IC₅₀ values and cell type. Alignment with recent best practices in cell viability assessment can mitigate inconsistencies (Schwartz 2022). For detailed workflow scenarios and troubleshooting, refer to the data-driven guide at PD-L1.com, which is extended here by offering updated solubility and selectivity considerations.

Conclusion & Outlook

YM-155 hydrochloride stands as a benchmark small-molecule survivin inhibitor for cancer research, enabling high-selectivity, reproducible apoptosis studies and tumor regression modeling. Its precise mechanism of action, robust evidence base, and compatibility with advanced workflows make it indispensable for dissecting IAP pathway biology and translational oncology research. Ongoing research may define novel applications and inform combinatorial strategies in preclinical settings. For validated protocols and ordering, consult the official APExBIO product page.